Literature DB >> 6025851

[Immunodepressive therapy in neurology].

P F Girard, G Aimard, H Pellet.   

Abstract

Mesh：

Substances：

Year:  1967        PMID： 6025851

Source DB:  PubMed          Journal:  Presse Med        ISSN： 0032-7867            Impact factor:   1.228


× No keyword cloud information.
  6 in total

1.  Cyclophosphamide in chronic progressive multiple sclerosis: a comparative study.

Authors:  L La Mantia; M Eoli; A Salmaggi; V Torri; C Milanese
Journal:  Ital J Neurol Sci       Date:  1998-02

2.  [Effect of heterologous antilymphocyte serum on experimental allergic encephalomyelitis].

Authors:  W Land; E Frick; R Roscher; W Brendel; A Baethmann
Journal:  Klin Wochenschr       Date:  1969-06-15

3.  Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study.

Authors:  W H Likosky; B Fireman; R Elmore; G Eno; K Gale; G B Goode; K Ikeda; J Laster; C Mosher; J Rozance
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-12       Impact factor: 10.154

4.  Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years.

Authors:  R E Gonsette; L Demonty; P Delmotte
Journal:  J Neurol       Date:  1977-02-17       Impact factor: 4.849

5.  Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis.

Authors:  Francesco Patti; Salvatore Lo Fermo
Journal:  Autoimmune Dis       Date:  2011-03-15

6.  Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis.

Authors:  Bruno Brochet; Mathilde S A Deloire; Paul Perez; Timothé Loock; Louise Baschet; Marc Debouverie; Sophie Pittion; Jean-Christophe Ouallet; Pierre Clavelou; Jérôme de Sèze; Nicolas Collongues; Patrick Vermersch; Hélène Zéphir; Giovanni Castelnovo; Pierre Labauge; Christine Lebrun; Mikael Cohen; Aurélie Ruet
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.